Skip to main content

Bayer inks a $1.5 billion deal for a biotech with a proprietary drug discovery platform

By Stat News  
   August 05, 2021

In a bid to quickly broaden its drug discovery abilities, Bayer (BAYRY) has reached a deal to acquire Vividion Therapeutics for $1.5 billion, the third time in two years the company has bought a small biotech with proprietary technology for uncovering medicines. Unlike the two earlier acquisitions, which gave Bayer entree to potential gene and cell therapies, the focus of this latest acquisition is primarily on oncology and immunology, although that can be expanded to other therapeutic areas.

Full story

Get the latest on healthcare leadership in your inbox.